Receptor for advanced glycation end products facilitates host defense during escherichia coliinduced abdominal sepsis in mice

Journal of Infectious Diseases

Volumn 200, Issue 5, 2009, Pages 765-773

  Van Zoelen, Marieke A D ^a,d   Schmidt, Ann Marie ^b   Florquin, Sandrine ^a   Meijers, Joost C ^a   De Beer, Regina ^a   De Vos, Alex F ^a   Nawroth, Peter P ^c   Bierhaus, Angelika ^c   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; CYTOKINE RELEASE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HOST RESISTANCE; INNATE IMMUNITY; LIVER; LIVER CELL DAMAGE; LUNG; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SEPSIS; ANIMAL; BACTERIAL COUNT; BLOOD; BLOOD CLOTTING; C57BL MOUSE; IMMUNOLOGY; MICROBIOLOGY; MOUSE MUTANT; PATHOLOGY;

ANIMALS; BLOOD COAGULATION; COLONY COUNT, MICROBIAL; CYTOKINES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; LIVER; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PERITONEAL CAVITY; RECEPTORS, IMMUNOLOGIC; SEPSIS;

EID: 70349310343     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/604730     Document Type: Article

References (48)

1. 1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310 (Pubitemid 32641789)
2. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214
3. McClean KL, Sheehan GJ, Harding GK. Intraabdominal infection: a review. Clin Infect Dis 1994; 19:100-116
4. Bierhaus A, Stern DM, Nawroth PR RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006; 7:985-991
5. 5. Chen Y, Yan SS, Colgan J, et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol 2004; 173:1399-1405 (Pubitemid 38924321)
6. Moser B, Desai DD, Downie MP, et al. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol 2007; 179:8051-8058
7. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81:1-5.
8. 8. Sorci G, Riuzzi F, Arcuri C, Giambanco I, Donato R. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol 2004; 24:4880-4894 (Pubitemid 38668053)
9. Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270:25752-25761
10. Moroz OV, Antson AA, Dodson EJ, et al. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr 2002; 58:407-413
11. 11. Valencia JV, Mone M, Zhang J, Weetall M, Buxton FP, Hughes TE. Divergent pathways of gene expression are activated by the RAGE ligands SlOOb and AGE-BSA. Diabetes 2004; 53:743-751 (Pubitemid 38270645)
12. 12. Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6:643-651 (Pubitemid 30398787)
13. 13. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-/cB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274:19919-19924 (Pubitemid 129519445)
14. 14. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-/cB. Diabetes 2001; 50:2792-2808 (Pubitemid 33733131)
15. 15. Chavakis T, Bierhaus A, Al Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198:1507-1515 (Pubitemid 37467165)
16. 16. Zen K, Chen CX, Chen YT, Wilton R, Liu Y. Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J Immunol 2007; 178:2483-2490 (Pubitemid 46233449)
17. 17. Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-1650 (Pubitemid 39071688)
18. Lutterloh EC, Opal SM, Pittman DD, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11:R122.
19. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005; 4:854-865
20. 20. Weijer S, Schoenmakers SH, Florquin S, et al. Inhibition of the tissue factor/factor Vila pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice. J Infect Dis 2004; 189:2308-2317 (Pubitemid 38757205)
21. Renckens R, Roelofs JJ, Florquin S, et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol 2006; 177:1189-1196
22. 22. Renckens R, Roelofs JJ, Florquin S, van der Poll T. Urokinase-type plasminogen activator receptor plays a role in neutrophil migration during lipopolysaccharide-induced peritoneal inflammation but not during Escherichia coli-induced peritonitis. J Infect Dis 2006; 193:522-530 (Pubitemid 43202743)
23. 23. Hofmann MA, Drury S, Fu Q et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97:889-901. (Pubitemid 29375048)
24. 24. Leemans JC, Vervoordeldonk MJ, Florquin S, van Kessel KP, van der Poll T. Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am J Respir Crit Care Med 2002; 165:1445-1450 (Pubitemid 34522951)
25. 25. Rijneveld AW, Weijer S, Florquin S, et al. Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004; 103:1702-1709 (Pubitemid 38268962)
26. 26. Zeng S, Feirt N, Goldstein M, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004; 39:422-432 (Pubitemid 38222183)
27. Cataldegirmen G, Zeng S, Feirt N, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-a and NF-xB. J Exp Med 2005; 201:473-484
28. Ekong U, Zeng S, Dun H, et al. Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 2006; 21:682-688
29. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect Immun 1997; 65:3847-3851
30. 30. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002; 283:R7-28. (Pubitemid 34863907)
31. van Zoelen MA, van der Poll T. Targeting RAGE in sepsis. Crit Care 2008; 12:103.
32. 32. Park JS, Svetkauskaite D, He Q, et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279:7370-7377 (Pubitemid 38294612)
33. 33. Yu M, Wang H, Ding A, et al. HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2. Shock 2006;26:174-179 (Pubitemid 44162504)
34. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290:C917-24.
35. van Zoelen MA, Yang H, Florquin S, et al. Role of Toll-like receptors 2 and 4, and the receptor for advanced glycation end products in highmobility group box 1-induced inflammation in vivo. Shock 2009; 31: 280-284
36. Sewnath ME, Olszyna DP, Birjmohun R, ten Kate FJ, Gouma DJ, van der Poll T. IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 2001; 166:6323-6331
37. 37. Lenz AM, Franklin GA, Fairweather M, et al. Endogenous IL-10 leads to impaired bacterial clearance and reduced survival in a murine model of chronic peritonitis. Cytokine 2007; 40:207-215 (Pubitemid 350213433)
38. 38. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530-538 (Pubitemid 36523666)
39. 39. Brown MA, Jones WK. NF-kB action in sepsis: the innate immune system and the heart. Front Biosci 2004; 9:1201-1217 (Pubitemid 39060836)
40. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389
41. 41. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-/cB dependent inflammatory response. Cardiovasc Res 2006; 72: 384-393 (Pubitemid 44665856)
42. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 2008; 102:1239-1246
43. 43. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59:1117-1128 (Pubitemid 34895406)
44. Bucciarelli LG, Ananthakrishnan R, Hwang YC, et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 2008; 57:1941-1951
45. 45. Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vase Biol 2001; 21:905-910 (Pubitemid 34168644)
46. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109:2698-2704
47. 47. Cai H, Song C, Endoh I, et al. Serum amyloid A induces monocyte tissue factor. J Immunol 2007; 178:1852-1860 (Pubitemid 46154658)
48. 48. Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sei U S A 2006; 103:13801-13806 (Pubitemid 44413988)